HHS Inspector General Postpones Study Of FDA Conflict-Of-Interest Oversight
This article was originally published in The Gray Sheet
Executive Summary
The HHS Office of Inspector General announced it will postpone a study of FDA and instead focus its conflict-of-interest enforcement efforts on the National Institutes of Health this year
You may also be interested in...
Postmarket Surveillance, Durable Equipment Payments On OIG Study List
A close look at FDA's medical device adverse event reporting system is one of the projects on the HHS Office of Inspector General's list for the coming year
Postmarket Surveillance, Durable Equipment Payments On OIG Study List
A close look at FDA's medical device adverse event reporting system is one of the projects on the HHS Office of Inspector General's list for the coming year
Ex-FDA Commissioner Pleads Guilty To Conflicts, False Statements
Former FDA Commissioner Lester Crawford pleaded guilty in D.C. federal court Oct. 17 to owning company stocks that caused conflicts of interest and to making false statements about those stock holdings during his tenure at the agency